Article info
Clinical ethics
Paper
The rise of reimbursement-based medicine: the case of bone metastasis radiation treatment
- Correspondence to Dr Marcos Santos, UNESCO Chair of Bioethics, Faculty of Health and Sciences, University of Brasilia, PO BOX 04451, CEP 70919-970 Brasilia, Federal District, Brazil; marcosrxt{at}gmail.com
Citation
The rise of reimbursement-based medicine: the case of bone metastasis radiation treatment
Publication history
- Received April 10, 2016
- Revised June 12, 2017
- Accepted July 17, 2017
- First published August 5, 2017.
Online issue publication
February 24, 2018
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.
Other content recommended for you
- Geographical distance and reduced access to palliative radiotherapy: systematic review and meta-analysis
- Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose?
- Retrospective analysis of characteristics associated with higher-value radiotherapy episodes of care for bone metastases in Medicare fee-for-service beneficiaries
- Managing metastatic bone pain
- Optimal dose-fractionation schedule of palliative radiotherapy for patients with bone metastases: a protocol for systematic review and network meta-analysis
- Managing skeletal related events resulting from bone metastases
- Radiation therapy in malignant spinal cord compression: what is the current knowledge on fractionation schedules? A systematic literature review
- Advances in radiotherapy
- Response assessment and outcome of combining immunotherapy and radiosurgery for brain metastasis from malignant melanoma
- Estimation of the additional costs of chemotherapy for patients with advanced non-small cell lung cancer